The unique regulatory challenges presented by human stem cells demand a more robust and efficient dialogue with the FDA. This forum will provide the insights needed to help navigate this process and successfully bring therapeutics to market.
Washington (PRWEB) April 08, 2014
DIA will host a forum called “FDA Regulation of Therapeutic Products Derived From Human Stem Cells: Successfully Navigating the Regulatory Hurdles” during the DIA 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19.
The Food and Drug Administration (FDA) regulates many therapeutic products derived from human stem cells. As part of the novel science of regenerative medicine, human stem cell research spans many FDA regulatory jurisdictions and poses particular challenges—like limited precedents from which to learn—for developing products safely and effectively. Understanding how to improve communications and interactions with FDA can help reduce risks for sponsors, more accurately identify FDA’s position on key issues and facilitate a smoother pathway to market.
“Our annual meeting is a global platform to better understand the full development and life cycle management process for all health care products, including therapeutics,” said Barbara L. Kunz, DIA global chief executive. “The unique regulatory challenges presented by human stem cells demand a more robust and efficient dialogue with the FDA. This forum will provide the insights needed to help navigate this process and successfully bring therapeutics to market.”
The forum, chaired by Dr. Ellen G. Feigal, senior vice president for research and development at the California Institute for Regenerative Medicine, will be held June 16 at 11 a.m. Feigal will describe the general FDA framework governing therapeutic products derived from human stem cells. She will also offer proven tips to identify and plan for successful management of specific regulatory issues that are likely to affect the development of these products.
ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Pa., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit http://www.diahome.org.
ABOUT DIA’s 2014 50th ANNUAL MEETING: Celebrate the Past – Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit http://www.diahome.org/dia2014.